We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Itaconix Plc | LSE:ITX | London | Ordinary Share | GB00BPK3YZ68 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-11.50 | -7.54% | 141.00 | 140.00 | 142.00 | 152.50 | 141.00 | 152.50 | 11,471 | 14:55:14 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Chemicals & Chem Preps, Nec | 7.87M | -1.54M | -0.1139 | -12.38 | 19.02M |
Date | Subject | Author | Discuss |
---|---|---|---|
05/6/2019 08:31 | Wonder why there was no operational update? Normally get one at the of may | pictureframe | |
04/6/2019 21:29 | In the Patient Capital Trust as far as I know but he's moving stocks to maintain weightings so who knows. | geraldus | |
04/6/2019 21:09 | Can anyone clarify if Woodford income fund holds Itaconix? I can't find the information anywhere. | wololol | |
04/6/2019 20:48 | Woodford probably selling a few. | geraldus | |
04/6/2019 14:36 | any idea about the severe drop? top up opportunity? anybody kindly L2? thx | the patient investor | |
30/5/2019 09:50 | Just need patience, these will take off sooner or later on improving news flow and fundamentals. Happy holding and buying pull backs, accumulating jobbie here! | ny boy | |
29/5/2019 08:00 | Excellent news - adds to cash reserrve | pictureframe | |
24/5/2019 16:16 | ….should've gone to Specsavers ? | dexdringle | |
21/5/2019 14:39 | This is what i thought Hence the share price trend Most of the trades today are buys I see 4p by the end of this month | the patient investor | |
21/5/2019 14:03 | 200k this am reported as a sell was a buy | jbe81 | |
21/5/2019 13:55 | Most of the trades are BUYS, reported incorrectly as sells. I expect another tick up soon. | the patient investor | |
21/5/2019 13:53 | think so can sell a lot at 3,42 | jbe81 | |
21/5/2019 13:40 | 3.49 is not a sell Just did a mock sell and was being offered 3.42 I mock bough a few shares and the ask was 3.49 A tick up soon i guess. L2 anybody? Tx | the patient investor | |
21/5/2019 12:43 | Although this is admittedly only a small order The initial process would probably have come from the In-Cosmetics Global expo in early April so the speed to get to RNS by now is pretty impressive. I think the tie up with Nouryon is going to prove a game changer. More to come. | ragnarr | |
21/5/2019 08:22 | Jonathansidwell21 May '19 - 08:17 - 1274 of 1275 (Filtered) | the patient investor | |
21/5/2019 08:17 | What a load of bollcks | jonathansidwell | |
21/5/2019 08:12 | Correct, this is what the CEO said in the recent interview | the patient investor | |
21/5/2019 08:03 | They had surpassed prev years sales by April this year. | pictureframe | |
21/5/2019 07:55 | the great thing is that Nouryon is so confident that asked ITX the exclusivity to sell the new personal care product and ITX has happily accepted to withdraw it from its own market channels. To me this aspect is the most important and will put us in the public view. 10p by year's end? dyoFr | the patient investor | |
21/5/2019 07:49 | Orders coming through and money coming in. Great to see first order for the AMAZE share price so soon after the global supply agreement. This could be massive. | wololol | |
21/5/2019 07:38 | Nice RNS - The story is coming together here | pictureframe | |
20/5/2019 13:51 | hxxps://theindustrya Nouryon has entered into a global supply agreement with the UK-based specialty polymers manufacturer Itaconix in furtherance of its plans to extend its range of products to its consumer base in the personal care market by adding bio-based polymers. This agreement marks the second deal that is an outcome of the joint development agreement signed back in 2017, which was aimed at exploring the prospects for polymers made using itaconic acid by employing Itaconix’s technology. The companies had previously announced a deal for bio-based polymers having chelating properties and Nouryon will market the products for the customers in the detergents industry. The specialty chemicals company, formerly AkzoNobel Specialty Chemicals, has been trying to broaden its range of offerings with innovative products for its customers in the personal care sector, which is a primary focus of the company’s business. The company has been working on various products like the newly introduced film-forming polymer that can be utilized in creating long-lasting, high SPF sunscreen products. Lynnette Bowen, Global Marketing Director, Personal Care believes that the customers are becoming more environmentally conscious and that is urging companies to make more natural, eco-friendly personal care products. Bowen also mentioned that including Itaconix’s proprietary polymers to Nouryon’s profile would help them enable their customers to create bio-based formulations without depleting the technical performance while also assisting them in meeting the ever-changing industry trends and demands of the customers. This is the second agreement between Nouryon and Itaconix, signifying a significant step by Itaconix in the direction of intensifying the footprint of the company and augmenting the value of the company’s novel polymers. Nouryon has also announced its plans to expand its product range for its customers in the fuels segment with via an exclusive global licensing agreement with SulNOx Group, a company engaged in hydrocarbon fuel emulsification and additives. The agreement entails that Nouryon will launch two new additives Berol 6446 and Berol 6430, the compounds that help enhance the combustion efficiency of diesel as well as low-viscosity heavy fuel oil (HFO) for power generation and transportation. | pictureframe |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions